V Hirsh
Overview
Explore the profile of V Hirsh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laurie S, Banerji S, Blais N, Brule S, Cheema P, Cheung P, et al.
Curr Oncol
. 2019 Mar;
26(1):e81-e93.
PMID: 30853813
Background: Little evidence has been generated for how best to manage patients with non-small-cell lung cancer (nsclc) presenting with rarer clinical scenarios, including oligometastases, oligoprogression, and pseudoprogression. In each of...
2.
Cheema P, Rothenstein J, Melosky B, Brade A, Hirsh V
Curr Oncol
. 2019 Mar;
26(1):37-42.
PMID: 30853796
For more than a decade, there has been no improvement in outcomes for patients with unresectable locally advanced (la) non-small-cell lung cancer (nsclc). The standard treatment in that setting is...
3.
Melosky B, Cheema P, Agulnik J, Albadine R, Bebb D, Blais N, et al.
Curr Oncol
. 2018 Nov;
25(5):317-328.
PMID: 30464681
Background: Inhibition of the anaplastic lymphoma kinase (alk) oncogenic driver in advanced non-small-cell lung carcinoma (nsclc) improves survival. In 2015, Canadian thoracic oncology specialists published a consensus guideline about the...
4.
Abdallah S, Hirsh V
Curr Oncol
. 2018 Jun;
25(Suppl 1):S9-S17.
PMID: 29910643
Despite recent advances in the systemic therapy of non-small-cell lung cancer (nsclc), the prognosis for stage iv disease remains poor. The discovery of targetable mutations has led to new treatment...
5.
6.
Melosky B, Chu Q, Juergens R, Leighl N, Ionescu D, Tsao M, et al.
Cancer Treat Rev
. 2018 Mar;
65:65-77.
PMID: 29567557
Background: Lung cancer is the most common cause of cancer-related death among males and the second leading cause among females globally. Checkpoint inhibitors re-engage the immune system to fight cancer....
7.
Paz-Ares L, Tan E, OByrne K, Zhang L, Hirsh V, Boyer M, et al.
Ann Oncol
. 2017 Apr;
28(2):270-277.
PMID: 28426106
Background: In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective response rate (ORR) versus gefitinib in patients with epidermal growth...
8.
Turgeon G, Souhami L, Kopek N, Hirsh V, Ofiara L, Faria S
Cancer Radiother
. 2017 Mar;
21(2):89-98.
PMID: 28325618
Purpose: Many Canadian institutions treat limited-disease small cell lung cancer with 40Gy in 15 fractions delivered once-a-day in 3weeks concomitantly with chemotherapy. This regimen is convenient and seems to be...
9.
Yang J, Sequist L, Zhou C, Schuler M, Geater S, Mok T, et al.
Ann Oncol
. 2016 Sep;
27(11):2103-2110.
PMID: 27601237
Background: Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). In the case of drug-related grade ≥3 or selected prolonged grade 2 adverse events...
10.
Melosky B, Agulnik J, Albadine R, Banerji S, Bebb D, Bethune D, et al.
Curr Oncol
. 2016 Jun;
23(3):196-200.
PMID: 27330348
Anaplastic lymphoma kinase (alk) is an oncogenic driver in non-small-cell lung cancer (nsclc). Chromosomal rearrangements involving the ALK gene occur in up to 4% of nonsquamous nsclc patients and lead...